You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in the US

Apr 2012

Price: US$2,400

About this Report

EXECUTIVE SUMMARY

Consumer health sales hit all-time high

Consumer health value sales reached their highest ever level in 2011. Despite lingering high unemployment and repeated government funding scares which hampered economic growth, consumer health again proved resilient. High healthcare costs and growing consumer interest in proactive solutions continued to drive sales of OTC products and vitamins and dietary supplements, while sports nutrition grew due to increasing mainstream appeal and interest in exercise supplementation.

Vitamins and dietary supplements performs the best

For the first time ever, sales of vitamins and dietary supplements surpassed those of OTC remedies in 2011. Growing interest in natural healthcare and preventative supplementation helped increase value sales of vitamin and dietary supplements. While OTC remedies remained popular, growth was hampered by continued recalls of products by global brand owner Johnson & Johnson Inc, sales erosion through private label growth, and the lack of a significant flu epidemic in 2011.

No end in sight for recalls

Johnson & Johnson witnessed another year of significant share losses through its US consumer health entity McNeil Consumer & Specialty Pharmaceuticals, as the company reeled from the continued recalls of many of its most popular brands. In March, the U.S. Food and Drug Administration (FDA) took control of three of Johnson & Johnson’s plants after repeated recalls and concerns about violations of current good manufacturing practices. Of the three plants, the Fort Washington, Pennsylvania, location was shut down completely. While Johnson & Johnson has committed US$100 million to improve the plant, as of early 2012, the site was not operational.

Distribution continues to consolidate

Internet retailing and parapharmacies/drugstores continued to capture distribution share in 2011. The former channel is particularly strong and fast-growing in sports nutrition and vitamins and dietary supplements. Parapharmacies/drugstores also gained good share and has been able to draw consumers in through its growing number of in-store clinics, strong loyalty programs, and aggressive discounting.

Growth expected to slow as categories mature, sluggish economy persists

Retail value sales are expected to grow slower over the forecast period than during the review period. The US economy is expected to continue to grow by lower-than-average rates through 2014, which along with an elevated unemployment rate will act as a damper on consumer spending. Furthermore, categories which experienced rapid growth over the review period, namely vitamins and dietary supplements and sports nutrition, will marginally slow as categories mature and private label and distribution evolution lead to lower prices. Despite health trends, OTC products are expected to witness the worst performance over the forecast period. The category is fairly mature, has a high rate of private label competition, and is dominated by parapharmacies/drugstores and hypermarkets, both of which channels have shown a penchant for massive discounting to drive volume. The lack of high-profile Rx-to-OTC switch candidates during the forecast will also negatively affect growth.


Samples (FAQs about samples):

doc_pdf.png Sample Consumer Health Market Research Report

doc_excel_table.png Sample Consumer Health Data

Delivery: Files are delivered directly into your account within a few minutes of purchase.

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in USA with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in USA, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in USA for free:

The Consumer Health in USA market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in USA?
  • What are the major brands in USA?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Table of Contents

Table of Contents

Consumer Health in the US - Industry Overview

EXECUTIVE SUMMARY

Consumer health sales hit all-time high

Vitamins and dietary supplements performs the best

No end in sight for recalls

Distribution continues to consolidate

Growth expected to slow as categories mature, sluggish economy persists

KEY TRENDS AND DEVELOPMENTS

Persistent recalls define another year in OTC

Acquisitions shake up OTC competitive landscape

Increasing media attention drives supplementation fever

Growing mainstream appeal catapults sports nutrition sales

Tonics and bottled nutritive drinks: The new mega-category

MARKET INDICATORS

  • Table 1 Consumer Expenditure on Health Goods and Medical Services 2006-2011
  • Table 2 Life Expectancy at Birth 2006-2011

MARKET DATA

  • Table 3 Sales of Consumer Health by Category: Value 2006-2011
  • Table 4 Sales of Consumer Health by Category: % Value Growth 2006-2011
  • Table 5 Consumer Health Company Shares 2007-2011
  • Table 6 Consumer Health Brand Shares 2008-2011
  • Table 7 Penetration of Private Label by Category 2006-2011
  • Table 8 Sales of Consumer Health by Distribution Format: % Analysis 2006-2011
  • Table 9 Sales of Consumer Health by Category and Distribution Format: % Analysis 2011
  • Table 10 Forecast Sales of Consumer Health by Category: Value 2011-2016
  • Table 11 Forecast Sales of Consumer Health by Category: % Value Growth 2011-2016

APPENDIX

OTC registration and classification

Vitamins and dietary supplements registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC - Switches 2009-2011

SOURCES

  • Summary 2 Research Sources

Consumer Health in the US - Company Profiles

Bayer Corp in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Bayer Corp: Competitive Position 2011

Chattem Inc in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Chattem Inc: Competitive Position 2011

CVS Caremark Corp in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 9 CVS Caremark Corp: Competitive Position 2011

Cytosport Inc in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 11 Cytosport Inc: Competitive Position 2011

General Nutrition Centers Inc in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 14 General Nutrition Centers Inc: Competitive Position 2011

GlaxoSmithKline Consumer Health in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 16 GlaxoSmithKline Consumer Health: Competitive Position 2011

McNeil Consumer & Specialty Pharmaceuticals in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 19 McNeil Consumer & Specialty Pharmaceuticals: Competitive Position 2011

NBTY Inc in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 22 NBTY Inc: Competitive Position 2011

Pfizer Consumer Healthcare Inc in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 24 Pfizer Consumer Healthcare Inc: Competitive Position 2011

Walgreen Co in Consumer Health (USA)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 27 Walgreen Co: Competitive Position 2011

Adult Mouth Care in the US - Category Analysis

HEADLINES

TRENDS

  • Driven by the dramatic growth of dry mouth remedies, current value sales in adult mouth care grew by 2% in 2011. An ageing population in the US combined with increasing usage of prescription drugs increased the incidence of dry mouth among consumers and continued to drive demand for OTC remedies. In addition, GlaxoSmithKline’s Biotene experienced an uptick in promotional activity, with television advertisements designed to inform consumers about dry mouth and its treatments. Biotene also made its products available in a wide range of forms that include mouth spray, gel, liquid, gum and oral rinse. This ensures that consumers can obtain relief from dry mouth symptoms in a variety of convenient forms. The dramatic growth of Biotene – which witnessed value sales grow by a total of 65% between 2008 and 2011 – was the major driver behind the recent growth in adult mouth care.

COMPETITIVE LANDSCAPE

  • Church & Dwight Co Inc retained a marginal lead in adult mouth care with a value share of 25% in 2011. The company is the leading player in providing oral pain relief from toothache or mouth sores. Despite its continued leadership, its value share declined steadily since it acquired the brand with a value share of 30% in 2008. Strong competition from private label products, which can compete on the basis of price, continued to erode the company’s share. Pfizer, the category’s third largest player, also saw its value share drop in 2011as its Anbesol brand (also an oral pain reliever) lost share to private label.

PROSPECTS

  • The future of adult mouth care is expected to be driven by the same factors that drove growth in recent years of the review period. Oral pain products will benefit from the continual ageing of the US population, which will need pain relief from dentures or heavy dental work. At the same time, growing numbers of older consumers – who are more likely to take medication regularly – will also benefit from dry mouth remedies like Biotene. For these reasons, adult mouth care is predicted to witness a constant value CAGR of -1% over the forecast period.

CATEGORY DATA

  • Table 12 Sales of Adult Mouth Care: Value 2006-2011
  • Table 13 Sales of Adult Mouth Care: % Value Growth 2006-2011
  • Table 14 Adult Mouth Care Company Shares by Value 2007-2011
  • Table 15 Adult Mouth Care Brand Shares by Value 2008-2011
  • Table 16 Forecast Sales of Adult Mouth Care: Value 2011-2016
  • Table 17 Forecast Sales of Adult Mouth Care: % Value Growth 2011-2016

Analgesics in the US - Category Analysis

HEADLINES

TRENDS

  • After a challenging 2010 marked by a series of major product recalls, McNeil’s position only worsened in 2011. In January, the company announced that it was recalling 43 million packages of Tylenol, Benadryl, Sudafed, and Sinutab products due to their manufacture at a Fort Washington, Pennsylvania, plant that may not have been cleaned properly. The company followed with subsequent recalls of Extra-Strength Tylenol and Tylenol 8-Hour in March and June of 2011 due to consumer reports of “musty odours” in the products. These recalls left many store shelves bare of Tylenol products and further damaged consumer perceptions of the company. In addition, many paediatric Tylenol and Motrin products recalled in the spring of 2010 were absent from store shelves throughout 2011. These recalls had a devastating effect on McNeil’s value share in analgesics, which at 14% was less than half of its pre-recall (2009) levels.

COMPETITIVE LANDSCAPE

  • For the first time in the entire review period, McNeil Consumer & Specialty Pharmaceuticals fell from its leading position in analgesics in 2011. Over the previous two years (2010-11), the company’s sales had been devastated by a series of major product recalls of its Tylenol and Motrin brands. These recalls cost the company hundreds of millions of dollars in sales and damaged consumer perceptions of these brand names. Motrin, for example, which was the third largest brand in analgesics in 2009, but ranked only twelfth in 2011. In addition, the company sold its St Joseph’s aspirin brand to ILEX Consumer Products Group in January 2011, further reducing its share. Overall, McNeil fell to third in analgesics in 2011 with a value share of 14% – less than half its 2009 level of 29%.

PROSPECTS

  • One major trend that will affect the future of analgesics is the country’s ageing and increasingly active population. The demographic and lifestyle patterns of ageing baby boomers in the US offer tremendous growth potential for analgesics. The growing demand is projected to help drive retail value sales by a CAGR of 1% in constant value terms. This potential will be even greater for brands that focus on marketing to the elderly with products that are positioned as arthritis-specific. Two segments which have been especially strong in this regard – aspirin and naproxen – are thereby expected to grow faster than the category average with constant value CAGRs of 1% and 3%, respectively, over the forecast period.

CATEGORY DATA

  • Table 18 Sales of Analgesics by Category: Value 2006-2011
  • Table 19 Sales of Analgesics by Category: % Value Growth 2006-2011
  • Table 20 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2006-2011
  • Table 21 Analgesics Company Shares by Value 2007-2011
  • Table 22 Analgesics Brand Shares by Value 2008-2011
  • Table 23 Forecast Sales of Analgesics by Category: Value 2011-2016
  • Table 24 Forecast Sales of Analgesics by Category: % Value Growth 2011-2016

Calming and Sleeping in the US - Category Analysis

HEADLINES

TRENDS

  • In January 2010, McNeil recalled nine lots of its leading brand Simply Sleep. In the following years, consumers reported that the brand had totally vanished from store shelves, forcing them to buy other brands or private label alternatives. The duration of this product’s disappearance devastated sales, and as of February 2012 the company’s website stated “[Simply Sleep] is currently not available on store shelves. To be alerted when TYLENOL® Simply Sleep becomes available, please sign up to receive email updates.” The scope of this recall had dramatic implications on calming and sleeping as a whole, as Simply Sleep was the second largest brand with a value share of 15% as recently as 2009.

COMPETITIVE LANDSCAPE

  • Chattem Inc remained as leader of calming and sleeping with a value share of 21% in 2011. The company continued to witness strong value sales growth for the year, as consumers turned from unavailable Simply Sleep products to its popular Unisom line. Advertisements for Unisom appeared on major television networks, as the company sought to draw consumers who had previously been reliant on Simply Sleep.

PROSPECTS

  • Consumer demand for calming and sleeping products is expected to grow over the forecast period. As trends in health and wellness drive consumers to want to sleep better, sleeping aids will likely become increasingly popular. This should help constant value sales of calming and sleeping to grow by a constant value CAGR of 3% over the forecast period – a rate largely in line with historical trends for the category.

CATEGORY DATA

  • Table 25 Sales of Calming and Sleeping: Value 2006-2011
  • Table 26 Sales of Calming and Sleeping: % Value Growth 2006-2011
  • Table 27 Calming and Sleeping Company Shares by Value 2007-2011
  • Table 28 Calming and Sleeping Brand Shares by Value 2008-2011
  • Table 29 Forecast Sales of Calming and Sleeping: Value 2011-2016
  • Table 30 Forecast Sales of Calming and Sleeping: % Value Growth 2011-2016

Cough, Cold and Allergy (Hay Fever) Remedies in the US - Category Analysis

HEADLINES

TRENDS

  • In 2011, Chattem Inc’s Allegra brand of antihistamine/allergy remedies (systemic) switched from Rx-to-OTC, representing one of the largest switches in the segment’s history. First stocked on store shelves in March, Chattem accompanied Allegra’s launch with significant promotional spending both in-store and via media outlets. Attractive end-caps and displays at major retailers heralded the brand’s switch, while television and online advertisements appeared with great frequency. With its switch from prescription to over-the-counter, the Allegra brand brought a massive new group of incremental consumers into the OTC arena. With these efforts, Allegra attained value share of 6% within cough, cold and allergy remedies in its first year after switching.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson Inc remained the category leader (in GBO terms) in 2011 with a 12% value share held among major brands like Tylenol, Benadryl, Sudafed, and Zyrtec. Despite this position, the company’s share has fallen dramatically – dipping from nearly 21% in 2009 to just over 12% in 2011 – on the back of major and repeated product recalls throughout 2010 and 2011. As a result of these recalls, consumers were unable to locate their traditional brands and were forced to choose alternative brands or private label equivalents. By 2011, what had once been a clearly dominant position for the company had slipped to a mere one percentage point value share lead.

PROSPECTS

  • Over the forecast period, retail sales growth is projected to slow down for cough, cold and allergy remedies to a CAGR of 1% in constant value terms. This predicted growth is significantly lower than what the category exhibited during the review period, due to the fact that Rx-to-OTC switches of Zyrtec and Allegra drove dramatic growth in 2008 and 2011, respectively. Looking forward, the potential for large Rx-to-OTC switches driving the dramatic growth rates of the review period is minimal over the forecast period.

CATEGORY DATA

  • Table 31 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 33 Sales of Decongestants by Category: Value 2006-2011
  • Table 34 Sales of Decongestants by Category: % Value Growth 2006-2011
  • Table 35 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2006-2011
  • Table 36 Sales of Paediatric Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2006-2011
  • Table 37 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2007-2011
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2008-2011
  • Table 39 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2011-2016
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2011-2016

Digestive Remedies in the US - Category Analysis

HEADLINES

TRENDS

  • In December 2010, Johnson & Johnson’s product recall woes were majorly reinforced in digestive remedies. First, the company (in its joint venture with Merck & Co) announced it was recalling 12.3 million bottles of Mylanta because the product’s labels did not inform consumers of the brand’s alcohol content. This recall was followed only days later by another involving over 13 million packages of Rolaids, this time on the heels of consumer reports of metal and wood particles in the products. As the company worked to resolve the quality control issues at its manufacturing plants, it reported that additional products, like Pepcid Complete, would remain unavailable throughout much of 2011. As a result, consumers switched to other digestive remedy brands or to private label. This large shift played an important role in eroding value sales and slowing growth within digestive remedies in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • The Procter & Gamble Co remained the leader of digestive remedies with its major brands Pepto-Bismol, Metamucil and Prilosec, retaining an overall value share of 17% in 2011. Despite the continued decline of its Prilosec proton pump inhibitor due to branded and private label competition, the company’s share remained relatively flat in 2011. This result stems from the performance of the company’s Metamucil laxative brand, which saw strong sales growth in 2011. After the brand’s successful partnership with Dr. Oz in 2011 which saw more than 80,000 fans enter a contest to meet the television personality, Metamucil revived the partnership in February 2012 during Heart Health Month. Once again, this partnership offers fans another chance to meet Dr. Oz live in the New York and should help Metamucil.

PROSPECTS

  • Proton pump inhibitors (PPIs), which has been the most dynamic segment in terms of driving growth within digestive remedies in recent years, will play a vital role moving forward. As the segment is now marked by competition between three major brands (Prilosec, Prevacid and Zegerid), it is likely to see increased levels of advertising spending, which should increase consumer awareness and help sales. In addition, it is possible that additional switches within the segment could occur and drive additional growth, with Pfizer’s Protonix, Eisai’s Aciphex, and AstraZeneca’s Nexium serving as potential candidates. At the same time however, the growth potential for PPIs is limited. The entry of private label lansoprazole (Prevacid) and omeprazole/sodium bicarbonate (Zegerid) should erode average unit price and value sales. At the same time, the prospect for future switches is somewhat limited by the fact that retailers already devote large amounts of shelf-space to PPIs, and they may be unwilling to stock additional brands if they make the switch. Given these factors, proton pump inhibitors is predicted to display a constant value CAGR of 2% over the forecast period.

CATEGORY DATA

  • Table 41 Sales of Digestive Remedies by Category: Value 2006-2011
  • Table 42 Sales of Digestive Remedies by Category: % Value Growth 2006-2011
  • Table 43 Digestive Remedies Company Shares by Value 2007-2011
  • Table 44 Digestive Remedies Brand Shares by Value 2008-2011
  • Table 45 Forecast Sales of Digestive Remedies by Category: Value 2011-2016
  • Table 46 Forecast Sales of Digestive Remedies by Category: % Value Growth 2011-2016

Ear Care in the US - Category Analysis

HEADLINES

TRENDS

  • In February 2012, Prestige Brands Inc announced that it had completed the acquisition of 17 OTC brands from GlaxoSmithKline Consumer Health in a US$660 million deal. This move stands to dramatically reshape the competitive landscape in ear care, as one of the brands involved in this deal was Debrox – the leading brand in ear care in 2011. With Prestige’s pre-existing presence in the category with its Murine brand, this move ensures that the company will dominate the category in the future, controlling every major non-homeopathic product available.

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline (GSK) remained as leader in ear care with a value share of 39% in 2011. The continued success of the company’s Debrox brand helped its share grow consistently, and its value share in the category expanded by 11 full percentage share points from its 2008 level of 28%. This strong performance is especially important considering that Prestige Brands Inc – the category’s second largest branded player with a 17% value share in 2011 – acquired Debrox from GlaxoSmithKline (GSK) in February 2012 as GSK looked to divest itself of what it deemed were “non-core brands.” Prestige moved in the exact opposite direction to GlaxoSmithKline in recent years, as its share more than halved since 2008. The acquisition of Debrox, therefore, stands to reverse Prestige’s fortunes in ear care and makes the company the dominant player in the category moving forward.

PROSPECTS

  • The performance of ear care in the post-recessionary environment of 2010 and 2011 does not bode well for its performance over the forecast period. Consumers have yet to return to the category, and many may have simply decided they can go without such products or to use alternatives. While the category is likely to return to current value sales growth, this will be slow given the lack of new product innovation and consumer interest in the category. This translates into a projected flat constant value CAGR over the forecast period.

CATEGORY DATA

  • Table 47 Sales of Ear Care: Value 2006-2011
  • Table 48 Sales of Ear Care: % Value Growth 2006-2011
  • Table 49 Ear Care Company Shares by Value 2007-2011
  • Table 50 Ear Care Brand Shares by Value 2008-2011
  • Table 51 Forecast Sales of Ear Care: Value 2011-2016
  • Table 52 Forecast Sales of Ear Care: % Value Growth 2011-2016

Emergency Contraception in the US - Category Analysis

HEADLINES

TRENDS

  • In February 2011, global brand owner Teva Pharmaceutical Industries Ltd filed a petition with the FDA to permit the sale of its Plan B One Step over-the-counter. Since 2006, age restrictions on the sale of emergency contraceptives have required that these products be sold behind the pharmacy counter. Consumers of at least 17 years of age are required to show identification to purchase the products, while those under 17 can only buy them with a prescription. Teva's petition, therefore, would make Plan B One Step freely available to all consumers, shelved next to other OTC remedies. After a rigorous debate, US Secretary of Health and Human Services Kathleen Sebelius took unprecedented action and used her power as the agency’s head to overrule both the FDA’s Center for Drug Evaluation and Research and FDA Commissioner Margaret Hamburg to prevent Teva’s petition. This move drew strong reactions from both sides of the political spectrum, as conservative interest groups lauded the decision while Teva, women’s groups, and medical associations decried the action. By February 2012, The Center for Reproductive Rights had already reopened a 2005 court case aimed at overturning the decision.

COMPETITIVE LANDSCAPE

  • After losing its leading position in emergency contraception to Watson Pharmaceuticals and its lower-priced Next Choice in 2010, Duramed Pharmaceuticals regained the top position with a value share of 53% in 2011. The launch of its Plan B One Step brand, which requires that consumers take only one pill instead of two pills spaced apart with the Next Choice brand, offers a significant convenience advantage that many consumers were willing to pay a premium to obtain. As a result, the company was able to significantly gain share over its lower-priced competitor in 2011.

PROSPECTS

  • In August 2010, the FDA approved Ella, a new prescription emergency contraceptive that could influence the future of the OTC emergency contraceptives. Ella (ulipristal acetate) caters to consumer demand for added convenience by claiming that it can prevent pregnancy when taken orally within 120 hours (five days) of unprotected sex. Currently, Next Choice and Plan B One Step must be used as soon as possible and are no longer effective if taken more than 72 hours after unprotected sex. This product is looking to take the “emergency” out of emergency contraception and give women more flexibility. The end of Ella’s market exclusivity in August 2015 could also result in an Rx-to-OTC switch which could affect the longer time horizon of the category.

CATEGORY DATA

  • Table 53 Sales of Emergency Contraception: Value 2006-2011
  • Table 54 Sales of Emergency Contraception: % Value Growth 2006-2011
  • Table 55 Emergency Contraception Company Shares by Value 2007-2011
  • Table 56 Emergency Contraception Brand Shares by Value 2008-2011
  • Table 57 Forecast Sales of Emergency Contraception: Value 2011-2016
  • Table 58 Forecast Sales of Emergency Contraception: % Value Growth 2011-2016

Eye Care in the US - Category Analysis

HEADLINES

TRENDS

  • Current value sales of eye care in 2011 continued to benefit from an ongoing confluence of positive forces that were major drivers behind growth. As the number of consumers using contact lenses expands, the demand for dry eye remedies continues to grow. At the same time, as people continue to undergo vision-improvement surgeries (like LASIK), the population dependent on over-the-counter dry eye relief grows. As the most common side effect of vision-improvement surgeries is the long-term use of dry eye remedies, this has proved to be a significant source of growth. Finally, the ageing population in the US is increasingly dependent on prescription medications, which often have dry eye as a side effect. All of these factors, therefore, combined to pull people into the category in search of dry eye relief and generated a perfect storm that delivered sales growth in 2011.

COMPETITIVE LANDSCAPE

  • Alcon Laboratories remained the leader in eye care with a value share of 22% in 2011. The company’s share increased in every year of the review period, gaining ground from its 18% share in 2006. Systane – the company’s flagship brand in the category – grew dramatically over the review period and was the largest brand in eye care with a value share of 16% in 2011. The Systane line features a variety of options that includes preservative-free options, which became increasingly important to consumers in recent years.

PROSPECTS

  • Most of the factors driving the recent growth in standard eye care also point to strong future growth. The ageing population in the US and increased usage of prescription medications should drive sales of dry eye remedies, as it is a major side effect of many of these medicines. In addition, the number of people using contact lenses and the population having undergone LASIK corrective eye surgery is also expected to grow significantly. Even demographic patterns like rapid population growth in the southern regions of the US – areas with drier and dustier climates – provide a promising picture for the future of dry eye remedies within standard eye care. For these reasons, standard eye care is expected to register a constant value CAGR of 2% over the forecast period.

CATEGORY DATA

  • Table 59 Sales of Eye Care by Category: Value 2006-2011
  • Table 60 Sales of Eye Care by Category: % Value Growth 2006-2011
  • Table 61 Standard Eye Care by Format: % Value Breakdown 2007-2011
  • Table 62 Standard Eye Care by Positioning: % Value Breakdown 2007-2011
  • Table 63 Eye Care Company Shares by Value 2007-2011
  • Table 64 Eye Care Brand Shares by Value 2008-2011
  • Table 65 Forecast Sales of Eye Care by Category: Value 2011-2016
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2011-2016

Herbal/Traditional Products in the US - Category Analysis

HEADLINES

TRENDS

  • As regulatory actions shook many non-herbal/traditional categories in 2011, herbal/traditional products was able to gain some of the lost share in categories such as cough, cold, and allergy (hay fever) remedies and analgesics. There is also a growing interest among American consumers in all natural and non-synthetic products, which will help the category grow in the future.

COMPETITIVE LANDSCAPE

  • Kraft Foods Inc remained the largest player in herbal/traditional products in 2011, although its value share remained flat at 7%. The company’s 2010 acquisition of Cadbury Adams USA LLC, which brought the Halls medicated confectionery brand under the packaged food giant’s fold, marked the company’s first foray into the category.

PROSPECTS

  • Herbal/traditional products is expected to increase by a 1% constant value CAGR over the forecast period, eventually reaching US$4.7 billion by 2016.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2006-2011
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2006-2011
  • Table 69 Herbal/Traditional Products Company Shares 2007-2011
  • Table 70 Herbal/Traditional Products Brand Shares 2008-2011
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2011-2016
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2011-2016

Medicated Skin Care in the US - Category Analysis

HEADLINES

TRENDS

  • Medicated skin care continued to benefit from growing consumer demand in a variety of specialty/niche segments. Hair loss treatments, for example, continued to benefit from an ageing population in the US and witnessed current value retail growth of 4% in 2011. Nappy (diaper) rash treatments also continued to grow – leaping 7% in current value terms in 2011 – as budget-minded parents overextend the time their children are spending in their diapers, which increases the incidence of diaper rash. Antiparasitics/lice (head and body) treatments also experienced growth in consumer demand from epidemic levels of lice and bedbugs in 2011. In these segments, economic and demographic trends stand as some of the most important factors driving growth, and they helped push current value sales of medicated skin care up by 1% in 2011.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson retained its dominant position within medicated skin care (in GBO terms), holding a 17% value share in 2011. The company’s leadership is the result of an amalgamation of several unrelated business units. The bulk of the company’s sales come from the Pfizer consumer healthcare acquisition, most notably brands like Rogaine and Neosporin. Johnson & Johnson is also a leading player in medicated shampoos with its Neutrogena brand – a respected skin care brand that has successfully managed to span both medicated and non-medicated skin care.

PROSPECTS

  • Medicated skin care in the US is very mature, with limited potential for future switches. For this reason, the category is expected to register slow constant value growth of 1% over the forecast period. Growth, however, will be disparate between segments. Some, such as hair loss treatments, nappy (diaper) rash treatments, antiparasitics/lice (head and body treatments), antipruritics, and cold sore treatments align positively with demographic trends and have proven their ability to innovate to help drive growth. Others, like medicated shampoos and haemorrhoid treatments, have witnessed little innovation and are unlikely to see growth over the forecast period.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2006-2011
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2006-2011
  • Table 75 Medicated Skin Care Company Shares by Value 2007-2011
  • Table 76 Medicated Skin Care Brand Shares by Value 2008-2011
  • Table 77 Hair Loss Treatments Brand Shares by Value 2008-2011
  • Table 78 Forecast Sales of Medicated Skin Care by Category: Value 2011-2016
  • Table 79 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2011-2016

NRT Smoking Cessation Aids in the US - Category Analysis

HEADLINES

TRENDS

  • The number of smokers in the US continued to decline, falling another 0.3% in 2011 despite a growing population. For those looking to quit, NRT smoking cessation aids continued to be a popular choice to help with the difficult process. In spite of this, current value sales of NRT smoking cessation aids remained flat in 2011, displaying only marginal growth. This stagnant performance in spite of continued consumer interest in these products was attributable to the rising popularity of private label products, which are typically priced at least 20% lower than branded options. As branded products continued to lose value share to private label alternatives, the average unit price of the category eroded, as well as its value sales growth.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline Consumer Health remained the category leader with 46% value share in 2011. Over the review period, private label competitors worked to slowly erode its leading position from a value share of 60% in 2006. Recent innovations, however, have worked to slow the progress of private label. In NRT gum, for example, the late 2007 launch of Nicorette Cinnamon Surge helped to slow GlaxoSmithKline’s share decline in this segment. In 2011, the company still held 47% value share in NRT gum, but this share is in danger of falling as private label manufacturer Perrigo received FDA approval to market cinnamon flavoured NRT gum in July 2011. Moving forward, the company will needs to work towards further innovation if it is to maintain its share.

PROSPECTS

  • Demand for smoking cessation aids is likely to remain strong during the forecast period as consumers continue to look for ways to quit smoking. In conjunction with general trends favouring health/wellness, consumer demand for NRT products is likely to be bolstered by government action in the coming years. Raising taxes on tobacco will be an attractive option to state governments which are facing large budget deficits, and these tax increases can be achieved in the name of public health. These taxes raise the cost of smoking for consumers and should increase the number of people looking to quit.

CATEGORY INDICATORS

  • Table 80 Number of Smokers by Gender 2006-2011

CATEGORY DATA

  • Table 81 Sales of NRT Smoking Cessation Aids by Category: Value 2006-2011
  • Table 82 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2006-2011
  • Table 83 NRT Gum Flavours: % Value Breakdown 2006-2011
  • Table 84 NRT Smoking Cessation Aids Company Shares by Value 2007-2011
  • Table 85 NRT Smoking Cessation Aids Brand Shares by Value 2008-2011
  • Table 86 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2011-2016
  • Table 87 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2011-2016

Sports Nutrition in the US - Category Analysis

HEADLINES

TRENDS

  • Mainstreaming is the word of the day in sports nutrition. As the popularity of products continues to grow among non-hardcore workout demographics, more mass retailers are offering assortments in an attempt to cash in on the fast-growing category. Sports nutrition is helping itself by increasing investment in advertising and certification. Programmes such as the National Sanitary Foundation’s NSF Certified for Sport are helping erase the common view of the category as consisting of dangerous or untested products used exclusively by extreme bodybuilders.

COMPETITIVE LANDSCAPE

  • Three years after acquiring leading player Optimum Nutrition Inc, Irish dairy concern Glanbia Plc added to its leading share within global brand owners in 2011 with the acquisition of Bio-Engineered Supplements &Nutrition Inc. The company accounted for 16% share of retail value sales in global brand owner terms.

PROSPECTS

  • Mainstreaming will continue to strengthen sports nutrition during the forecast period, as total retail value sales are expected to increase by 35% to reach US$5.4 billion in constant value terms. As more casual athletes adopt light supplementation and non-athlete groups such as vegetarians and vegans use sports nutrition for protein supplementation, retailers will continue to increase their offerings across all segments, thus exposing even more consumers to the products.

CATEGORY DATA

  • Table 88 Sales of Sports Nutrition: Value 2006-2011
  • Table 89 Sales of Sports Nutrition: % Value Growth 2006-2011
  • Table 90 Sports Nutrition Company Shares 2007-2011
  • Table 91 Sports Nutrition Brand Shares 2008-2011
  • Table 92 Forecast Sales of Sports Nutrition: Value 2011-2016
  • Table 93 Forecast Sales of Sports Nutrition: % Value Growth 2011-2016

Vitamins and Dietary Supplements in the US - Category Analysis

HEADLINES

TRENDS

  • In the US, where healthcare is expensive and non-universal and the unemployment rate remains stubbornly high, there is a large and growing interest in preventative health care. In 2011, vitamins and dietary supplements continued to benefit from health claims aimed at everything from pregnancy nutrition to brain function to preventing colon cancer helped propel the category forward in 2011.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Vitamins and dietary supplements in the US remained highly fragmented. In 2011, the top five companies accounted for only 19% value share, while private label products accounted for another 13%.

PROSPECTS

  • Vitamins and dietary supplements is expected to grow by a 4% constant value CAGR over the forecast period, eventually reaching US$26.8 billion in 2016. This estimate is higher than predicted the previous year, due to revised growth projections of several large segments, namely tonics and bottled nutritive drinks, vitamin D, and omega 3-6-9 (fish and non-fish) products, which are all expected to enjoy continued strong growth through to 2016.

CATEGORY DATA

  • Table 94 Sales of Vitamins and Dietary Supplements by Category: Value 2006-2011
  • Table 95 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2006-2011
  • Table 96 Dietary Supplements by Positioning 2006-2011
  • Table 97 Vitamins and Dietary Supplements Company Shares by Value 2007-2011
  • Table 98 Vitamins and Dietary Supplements Brand Shares by Value 2008-2011
  • Table 99 Vitamins Brand Shares by Value 2008-2011
  • Table 100 Dietary Supplements Brand Shares by Value 2008-2011
  • Table 101 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2011-2016
  • Table 102 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2011-2016
  • Summary 28 Dietary Supplements: Brand Ranking by Positioning 2011

Weight Management in the US - Category Analysis

HEADLINES

TRENDS

  • At 2%, retail sales growth of weight management products was higher in 2011 than the review period average. While 2011 was a strong year for several new brands of meal replacement slimming and weight loss supplements, growth of the review period was weighed on heavily by declines during the heart of the recession in 2009 and several prominent recalls.

COMPETITIVE LANDSCAPE

  • Herbalife International Inc experienced another year of strong growth in weight management, and was able to increase its leading share to 9% in 2011. The company is particularly strong in meal replacement slimming, where it accounts for 13% value share. As a direct seller with strong ties to Latin American markets, Herbalife has experienced success building its brand among the US’s large and fast-growing Hispanic population. This foundation bodes well for the company’s weight management sales moving forward, as according to the US Centers for Disease Control and Prevention, the rate of obesity is higher among Hispanics than the general population.

PROSPECTS

  • While constant retail value sales of weight management are expected to increase slowly throughout the forecast period, growth rates in the constituent segments are expected to show strongly disparate growth rates. Weight management overall is expected to increase by a 1% constant value CAGR to reach US$4.2 billion. This growth rate is almost identical to that of the review period, which was weighed down by the recessionary negative dip in 2009.

CATEGORY DATA

  • Table 103 Sales of Weight Management: Value 2006-2011
  • Table 104 Sales of Weight Management: % Value Growth 2006-2011
  • Table 105 Weight Management Company Shares 2007-2011
  • Table 106 Weight Management Brand Shares 2008-2011
  • Table 107 Forecast Sales of Weight Management: Value 2011-2016
  • Table 108 Forecast Sales of Weight Management: % Value Growth 2011-2016

Wound Care in the US - Category Analysis

HEADLINES

TRENDS

  • As consumers emerge from one of the most severe recessions in US history, they remain highly price-sensitive and are focused on getting the best value for their money; a trend clearly exhibited in wound care in 2011. First, consumers chose to buy sticking plasters, adhesive bandages, gauze, and antiseptics as they needed them, rather than purchase complete and readymade first aid kits, which witnessed current value sales, fall by 13% in 2011. At the same time, private label products – which retail at prices of around 20% lower than branded options – experienced significant share gains for the year. This trend was intensified by a lack of branded innovation in 2011, which only intensified consumer focus on price.

COMPETITIVE LANDSCAPE

  • Johnson & Johnson Consumer Products Inc remained the category leader in 2011 with 52% value share. Its iconic Band-Aid brand has become a generic term, with many US consumers referring to any sticking plaster as a “Band-Aid”. Despite continued promotional efforts, the company continued to lose share to lower-priced private label products.

PROSPECTS

  • Sales of wound care products are expected to rise by a slow constant value CAGR of 1% over the forecast period. Wound care is highly commoditised and has virtually 100% household penetration. Even though Medline, Johnson & Johnson and 3M will seek to drive growth through product innovation, private label manufacturers will be quick to copy these new product developments and sell them at lower price points, thus depressing value growth.

CATEGORY DATA

  • Table 109 Sales of Wound Care by Category: Value 2006-2011
  • Table 110 Sales of Wound Care by Category: % Value Growth 2006-2011
  • Table 111 Wound Care Company Shares by Value 2007-2011
  • Table 112 Wound Care Brand Shares by Value 2008-2011
  • Table 113 Forecast Sales of Wound Care by Category: Value 2011-2016
  • Table 114 Forecast Sales of Wound Care by Category: % Value Growth 2011-2016

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Paediatric Analgesics
            • Paediatric Acetaminophen
            • Paediatric Aspirin
            • Paediatric Combination Products - Analgesics
            • Paediatric Diclofenac
            • Paediatric Dipyrone
            • Paediatric Ibuprofen
            • Paediatric Ketoprofen
            • Paediatric Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Paediatric Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
      • Protein Products
        • Bars
        • Powder
        • RTD
        • Other Protein
      • Non-Protein Products
    • Vitamins and Dietary Supplements
      • Paediatric Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Fibre
            • Green Tea Extract
            • Mangosteen Juice
            • Noni
            • Saw Palmetto
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Paediatric Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Paediatric Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Paediatric Consumer Health
        • Paediatric Analgesics
          • Paediatric Acetaminophen
          • Paediatric Aspirin
          • Paediatric Combination Products - Analgesics
          • Paediatric Diclofenac
          • Paediatric Dipyrone
          • Paediatric Ibuprofen
          • Paediatric Ketoprofen
          • Paediatric Naproxen
        • Paediatric Cough, Cold and Allergy Remedies
          • Paediatric Allergy Remedies
          • Paediatric Cough/Cold Remedies
        • Paediatric Digestive Remedies
          • Paediatric Diarrhoeal Remedies
          • Paediatric Indigestion and Heartburn Remedies
          • Paediatric Laxatives
          • Paediatric Motion Sickness Remedies
        • Paediatric Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Paediatric Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking population - number of adult smokers
    • Smoking prevalence - % of adult population

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    If you purchase a report that is updated in the next 60 days, we will send you the new edition of the report and the data extract FREE!